Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 57.1%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Haloperidol discontinuation vs haloperidol continuation

Global state: 2. Clinically important change (no improvement) ‐ long term · schizophrenia

It is very uncertain whether haloperidol discontinuation changes global state: clinically important change ‒ not improved (CGI) compared with haloperidol continuation (very low certainty).

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
RR 2.06 [1.33, 3.2]
1 study · 49 participants
Very low

Haloperidol discontinuation vs haloperidol continuation

Relapse · schizophrenia

It is very uncertain whether haloperidol discontinuation changes global state: relapse: ‒ compared with haloperidol continuation (very low certainty).

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
RR 1.8 [1.18, 2.74]
4 studies · 165 participants
Very low

Haloperidol discontinuation vs haloperidol continuation

Mental state: clinically important change in mental state · schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Haloperidol discontinuation vs haloperidol continuation

General functioning: clinically important change in general functioning including working ability · schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Haloperidol discontinuation vs haloperidol continuation

Behaviour: clinically important change in general behaviour · schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Haloperidol discontinuation vs haloperidol continuation

Quality of life: clinically important change in quality of life · schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Haloperidol discontinuation vs haloperidol continuation

Satisfaction with treatment: leaving the study early Endpoint data (events) · schizophrenia

It is very uncertain whether haloperidol discontinuation changes satisfaction with treatment: leaving the study early compared with haloperidol continuation (very low certainty).

1 finding from 1 review

Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
RR 0.13 [0.01, 2.28]
1 study · 43 participants
Very low